$0.03
(Market cap
$163 Mln
Recently Viewed
Clear AllMarket cap
$163 Mln
Revenue (TTM)
$16 Mln
P/E Ratio
--
P/B Ratio
3
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2.1
Debt to Equity
0.3
Book Value
$0.5
EPS
$-0.4
Face value
--
Shares outstanding
105,361,064
CFO
€-302.99 Mln
EBITDA
€-421.80 Mln
Net Profit
€-410.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
| -22.3 | 14.6 | -3.1 | -3.7 | -10.4 | -24.5 | -11.8 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
| -23.8 | -46.5 | -53.8 | 90.7 | -57.6 | -37.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ProQR Therapeutics N.V. - ADR
|
1.6 | 163.3 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 3.0 |
| 1.9 | 107.0 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 2.2 | |
| 30.0 | 1,872.6 | 0.0 | -176.1 | -- | -60.4 | -- | 5.9 |
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders... with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Read more
Founder & Independent Chairman of Supervisory Board
Dr. Domenico Valerio Ph.D.
Founder & Independent Chairman of Supervisory Board
Dr. Domenico Valerio Ph.D.
Headquarters
Leiden
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ProQR Therapeutics NV - ADR is $1.57 (NASDAQ) as of 30-Apr-2026 10:34 EDT. ProQR Therapeutics NV - ADR has given a return of -10.36% in the last 3 years.
Since, TTM earnings of ProQR Therapeutics NV - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.23
|
4.30
|
|
2024
|
-8.21
|
2.57
|
|
2023
|
-5.70
|
3.51
|
|
2022
|
-4.14
|
3.97
|
|
2021
|
-8.44
|
4.50
|
The 52-week high and low of ProQR Therapeutics NV - ADR are Rs 3.10 and Rs 1.33 as of 30-Apr-2026.
ProQR Therapeutics NV - ADR has a market capitalisation of $ 163 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ProQR Therapeutics NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.